GAA
Lysosomal alpha-glucosidase
As of the edition of 20 October 2026, GAA (lysosomal alpha-glucosidase, UniProt P10253) has 4 drugs tested at it and 8 companies on the list, 2 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P10253
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 19
- Disease areas
- Nutrition and metabolism; Hormones; Infections; Digestive system; Immune system; Urinary and reproductive; Inherited and neonatal; Nervous system
- Registered trials of its drugs
- 26
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Went quiet | 2 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Voglibose | Marketed | Phase 4 | none listed |
| Celgosivir | Went quiet | Phase 2 | none listed |
| Miglitol | Marketed | Phase 3 | none listed |
| Duvoglustat | Went quiet | Phase 2 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 2 |
| Undetermined | 4 |
| Total on the list | 8 |
| Company | Route |
|---|---|
| Pfizer | Route B |
| Sanwa Kagaku Kenkyusho | Route B |
| Sanofi | Route A |
The other 5 companies at GAA
In the product8 companies in all; 5 are not named here, and no score is.
See the 8 companies at GAA, ranked, with the facts behind eachRequest access. Nothing is shown until you do.